AnaptysBio

AnaptysBio completed the TRAX spinoff in April 2026 and now operates as a royalty management company overseeing its financial collaborations with GSK and Vanda. Piper Sandler lowered the price target to $93 from $95 on May 4 but kept an Overweight rating, citing the separation’s role in protecting and optimizing royalty value. The Delaware Chancery Court dismissed Tesaro’s anticipatory breach claim related to the Jemperli collaboration, supporting AnaptysBio’s position that it did not repudiate the agreement. » Más en finance.yahoo.com

AnaptysBio’s stock rose to a 52-week high of $68.46 and is currently trading at $68.53, implying a market capitalization of about $1.96 billion and a year-to-date performance of 320.01%. The company announced the spin-off of First Tracks Biotherapeutics, to be completed on April 20, 2026; shareholders will receive one share of First Tracks for each AnaptysBio share. First Tracks raised $80 million in a private placement at $13.81 per share. The board approved a $100 million share buyback program; analyst price targets range from $66 to $95, while InvestingPro rates the stock as overvalued compared with its fair value. » Más en de.investing.com

AnaptysBio is spinning off First Tracks Biotherapeutics; the distribution of all First Tracks shares to AnaptysBio shareholders is scheduled for April 20, 2026. Shareholders who hold AnaptysBio common stock as of April 6, 2026 will receive one First Tracks common share for each AnaptysBio share (1:1). Regular trading of First Tracks common stock under the ticker TRAX on the Nasdaq is expected to begin April 20, with when‑issued trading under TRAXV to start on April 6. The SEC declared the registration statement effective on April 1; completion of the spinoff is subject to certain conditions set forth in the prospectus. » Más en de.investing.com